Does dual antiplatelet therapy for 30 months reduce stent thrombosis and major adverse cardiovascular and cerebrovascular events in patients after placement of a drug-eluting stent?
Patients after placement of a drug-eluting stent
Dual antiplatelet therapy for 30 months
Aspirin therapy alone (after 12 months of dual antiplatelet therapy)
Stent thrombosis and major adverse cardiovascular and cerebrovascular eventscomposite
Extending dual antiplatelet therapy to 30 months after drug-eluting stent placement reduces ischemic events and stent thrombosis but increases bleeding compared to standard 12-month therapy.
Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Laura Mauri
Larry S. Dean
Robert W. Yeh
New England Journal of Medicine
Harvard University
Stanford University
Brigham and Women's Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Mauri et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69cea11e5ff5f19319758b5c — DOI: https://doi.org/10.1056/nejmoa1409312